AKT1 and neoplasm: Interestingly, in hepatocellular carcinoma, bergapten was reported to inhibit liver carcinogenesis through modulation of LXR/PI3K/AKT and IDOL/LDLR pathways both in vitro and in vivo, suggesting a role in tumor metabolism and cholesterol regulation [141].